Inactive/Delisted stock
Cingulate Stock (NASDAQ:CING)
Previous Close
$3.99
52W Range
$3.02 - $11.88
50D Avg
$4.54
200D Avg
$4.31
Market Cap
$22.06M
Avg Vol (3M)
$130.93K
Beta
-0.75
Div Yield
-
CING Company Profile
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.